A 57-year-old man comes to the physician because of a 3-month history of mild shortness of breath with exertion and episodes of nausea and muscle pain. He received the diagnosis of type 2 diabetes mellitus 8 years ago. Current medications include glyburide and metformin. He is 180 cm (5 ft 11 in) tall and weighs 118 kg (260 lb); BMI is 36 kg/m2 . His blood pressure is 165/90 mm Hg. The remainder of the examination shows no abnormalities. Laboratory studies show: Hemoglobin A 1c 9.2% Serum Urea nitrogen Glucose, fasting Creatinine Total bilirubin AST ALT 43 mg/dL 287 mg/dL 2.8 mg/dL 0.8 mg/dL 18 U/L 20 U/L Which of the following is the most appropriate change to this patient's drug regimen
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
This gives a comprehensive, authoritative answer. Here is the full analysis:
Most Appropriate Drug Regimen Change: Discontinue Metformin (and Glyburide)
Parsing the Clinical Data
| Finding | Value | Significance |
|---|---|---|
| Serum creatinine | 2.8 mg/dL | Severely elevated - indicates CKD stage 3b-4 |
| BUN | 43 mg/dL | Elevated, confirms renal impairment |
| HbA1c | 9.2% | Poor glycemic control |
| BMI | 36 kg/m2 | Obese |
| BP | 165/90 | Hypertensive |
| Symptoms | Nausea, muscle pain, dyspnea | Can be side effects of metformin accumulation |
Estimated eGFR: Using the CKD-EPI formula for a 57-year-old male with creatinine 2.8 mg/dL, eGFR is approximately 20-25 mL/min/1.73 m2 - consistent with CKD Stage 4.
Why Both Current Drugs Must Be Stopped
1. Discontinue Metformin (most critical)
Goldman-Cecil Medicine states directly:
"Because of the potentially increased risk of lactic acidosis with metformin therapy in patients who have renal insufficiency, treatment guidelines currently recommend not administering it to patients with serum creatinine of greater than 1.7."
This patient's creatinine is 2.8 mg/dL - far above the 1.7 threshold. Metformin is renally cleared, and in renal failure it accumulates and causes metformin-associated lactic acidosis (MALA). The patient's nausea and muscle pain are classic prodromal symptoms of early lactic acidosis from metformin accumulation.
2. Discontinue Glyburide (also important)
Goldman-Cecil Medicine also states:
"Because of the increased risk of prolonged hypoglycemia, use of sulfonylureas is contraindicated in patients with stage 3b chronic kidney disease or worse (e.g., a GFR <45)."
Glyburide is a long-acting sulfonylurea whose active metabolites are renally excreted. In CKD, these accumulate, causing dangerous prolonged hypoglycemia. Of all sulfonylureas, glyburide is particularly hazardous in renal impairment.
What to Replace With
Given the CKD, the textbook (Goldman-Cecil Medicine, p. Stage III management) recommends:
- Insulin - safe in renal failure (dose may need reduction as kidney fails to degrade insulin); becomes the mainstay of therapy
- SGLT2 inhibitors (e.g., canagliflozin, empagliflozin, dapagliflozin) - if eGFR is adequate enough; they also provide renoprotective and cardiovascular benefits. However, at eGFR ~20-25 they lose glycemic efficacy and are generally not started de novo
- GLP-1 receptor agonists - can be used in CKD (some require dose adjustment)
For this patient's eGFR of ~20-25, the most appropriate replacement is insulin therapy.
Additional Management
- Start an ACE inhibitor or ARB for his hypertension (BP 165/90) - these provide renoprotective and cardioprotective effects in diabetic nephropathy (Goldman-Cecil, Stage III: "BP control - ACEI or ARB")
- His shortness of breath with exertion may reflect early heart failure or anemia of CKD - worth evaluating
Summary Answer
The most appropriate change is to discontinue metformin (contraindicated with creatinine >1.7 mg/dL due to lactic acidosis risk) and discontinue glyburide (contraindicated when GFR <45 due to hypoglycemia risk from accumulated active metabolites), then initiate insulin for glycemic control. This directly explains his presenting symptoms: nausea and muscle pain are classic signs of metformin-associated lactic acidosis building up in the context of reduced renal clearance.
- Goldman-Cecil Medicine, Glycemic Control section (Chapter 109): serum creatinine >1.7 and sulfonylurea contraindication at GFR <45 in CKD
This is a shared conversation. Sign in to Orris to start your own chat.